RxDoctor Payments Data

Stephanie Meyer, APRN

Family · Phoenix, AZNPI 1790334233

Payments from drug & device makers

$5,682in general payments, 2019–2025

Across 112 payments — averaging $50.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Abbott$636
  • Edwards Lifesciences$614
  • Amgen$458
  • Boston Scientific$392
  • Abiomed$374
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$5,682100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,682 in reported general payments places this provider in the 90th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$102,094
Medicare patients
476
Services billed
1,375

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban196$225,376
JardianceEmpagliflozin30$37,473
XareltoRivaroxaban23$30,255
FarxigaDapagliflozin Propanediol11$14,605
EntrestoSacubitril/Valsartan11$8,062
Ranolazine ErRanolazine38$3,935
EdarbiAzilsartan Medoxomil12$2,974
Potassium Chloride131$2,587
Flecainide Acetate51$2,320
Diltiazem 24hr Er (Cd)Diltiazem Hcl62$2,057
Midodrine Hcl44$1,988
Metoprolol Succinate129$1,897
Isosorbide Mononitrate ErIsosorbide Mononitrate110$1,724
Rosuvastatin Calcium138$1,698
Valsartan48$1,539

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$225,376196 claims
Johnson & JohnsonXarelto$189$30,25523 claims
NovartisEntresto$289$8,06211 claims
Arbor Pharmaceuticals, Inc.Edarbi$12$2,97412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,119 family providers in Arizona.

Other family in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →